{
    "id": 6170,
    "name": "ovarian carcinosarcoma",
    "source": "DOID",
    "definition": "A malignant ovarian surface epithelial-stromal neoplasm that is a mixed cell type cancer that has_material_basis_in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938474/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:6170",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00954174",
            "title": "Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1125,
                    "therapyName": "Ifosfamide + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00989651",
            "title": "Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3047,
                    "therapyName": "Bevacizumab + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02269293",
            "title": "Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2640,
                    "therapyName": "Carboplatin + Paclitaxel + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02432378",
            "title": "Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9759,
                    "therapyName": "Celecoxib + Cisplatin + Interferon alpha-2b + Rintatolimod",
                    "synonyms": null
                },
                {
                    "id": 9758,
                    "therapyName": "Celecoxib + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03241745",
            "title": "A Study of Nivolumab in Selected Uterine Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03574779",
            "title": "Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer (OPAL)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7537,
                    "therapyName": "Bevacizumab + Niraparib + TSR-042",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03602859",
            "title": "A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6321,
                    "therapyName": "Niraparib + TSR-042",
                    "synonyms": null
                },
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03610490",
            "title": "Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9757,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03737643",
            "title": "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7489,
                    "therapyName": "Bevacizumab + Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7490,
                    "therapyName": "Bevacizumab + Durvalumab + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 2117,
                    "therapyName": "Bevacizumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03924245",
            "title": "Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1541,
                    "therapyName": "Entinostat",
                    "synonyms": null
                },
                {
                    "id": 8200,
                    "therapyName": "Entinostat + Olaparib",
                    "synonyms": null
                }
            ]
        }
    ]
}